In contrast to established prostate cancer cell lines, this approach provides the flexibility to model Brca2 loss in primary cells together with co-occurring genomic alterations commonly seen in BRCA2-mutant human CRPC. This evidence concerns the gene BRCA2 and Familial prostate cancer.